Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Ensartinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms eXalt3
- Sponsors Xcovery Holdings
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2016 Status changed from not yet recruiting to recruiting, as per Xcovery media release.